Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma

Summary by Floyd Chronicle & Times
SHANGHAI and HONG KONG, Aug. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced…

29 Articles

keenesentinel.comkeenesentinel.com
+28 Reposted by 28 other sources
Center

Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma

SHANGHAI and HONG KONG, Aug. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic malignancies and solid tumors, today announced…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 47% of the sources are Center
47% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States on Tuesday, August 19, 2025.
Sources are mostly out of (0)

Similar News Topics

Shanghai, China icon

Shanghai, China

News
For You
SearchBlindspotLocal